{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:43:08Z","timestamp":1784860988999,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ejca.2022.09.008","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T17:29:34Z","timestamp":1664990974000},"page":"100-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis"],"prefix":"10.1016","volume":"176","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8264-8182","authenticated-orcid":false,"given":"Frederik O.","family":"Meeuwes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirian","family":"Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein W.M.","family":"van der Poel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00eblle","family":"Wondergem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim G.N.J.","family":"Mutsaers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"B\u00f6hmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7840-6156","authenticated-orcid":false,"given":"Sherida","family":"Woei-A-Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimke","family":"Oostvogels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2361-9303","authenticated-orcid":false,"given":"Patty M.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9239-1050","authenticated-orcid":false,"given":"Arjan","family":"Diepstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjeerd J.F.","family":"Snijders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter J.","family":"Plattel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin A.","family":"Huls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost S.P.","family":"Vermaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2740-2873","authenticated-orcid":false,"given":"Marcel","family":"Nijland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.09.008_bib1","series-title":"WHO classification of tumours of hematopoietic and Lymphoid Tissues","first-page":"345","article-title":"Mature T- and NK-cell neoplasms","author":"Swerdlow","year":"2017"},{"issue":"10","key":"10.1016\/j.ejca.2022.09.008_bib2","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish lymphoma registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.ejca.2022.09.008_bib3","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.09.008_bib4","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/bjh.13202","article-title":"Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era","volume":"168","author":"Petrich","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2022.09.008_bib5","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.3324\/haematol.2015.126300","article-title":"Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets","author":"De Leval","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2022.09.008_bib6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/oxfordjournals.annonc.a059281","article-title":"Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation","author":"Siegert","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.09.008_bib7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1046\/j.1365-2141.2003.04335.x","article-title":"Angioimmunoblastic T-cell lymphoma","volume":"121","author":"Dogan","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2022.09.008_bib8","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/MD.0b013e3181573059","article-title":"Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients","volume":"86","author":"Lachenal","year":"2007","journal-title":"Medicine"},{"key":"10.1016\/j.ejca.2022.09.008_bib9","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the groupe d'Etude des lymphomes de l'Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ejca.2022.09.008_bib10","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells","volume":"109","author":"De Leval","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.09.008_bib11","doi-asserted-by":"crossref","first-page":"10703","DOI":"10.1158\/0008-5472.CAN-07-1708","article-title":"Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation","volume":"67","author":"Piccaluga","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2022.09.008_bib12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/bjh.12941","article-title":"Follicular helper T-cells: expanding roles in T-cell lymphoma and targets for treatment","volume":"166","author":"Ahearne","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2022.09.008_bib13","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3324\/haematol.2011.061507","article-title":"Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA","volume":"97","author":"Delfau-Larue","year":"2012","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.ejca.2022.09.008_bib14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.immuni.2014.10.004","article-title":"T follicular helper cell differentiation, function, and roles in disease","volume":"41","author":"Crotty","year":"2014","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.ejca.2022.09.008_bib15","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1182\/blood.V80.7.1804.1804","article-title":"Heterogeneous epstein-barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type","volume":"80","author":"Anagnostopoulos","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.09.008_bib16","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1182\/blood.V79.7.1789.1789","article-title":"Detection and localization of epstein-barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma","volume":"79","author":"Weiss","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.09.008_bib17","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.3324\/haematol.2016.158428","article-title":"Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin","volume":"102","author":"Dobay","year":"2017","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.ejca.2022.09.008_bib18","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2011-08-374371","article-title":"Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan","volume":"119","author":"Tokunaga","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.09.008_bib19","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41375-020-0990-y","article-title":"Advances in understanding of angioimmunoblastic T-cell lymphoma","volume":"34","author":"Chiba","year":"2020","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.ejca.2022.09.008_bib20","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-hodgkin lymphoma study group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.09.008_bib21","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2147\/OTT.S189825","article-title":"Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis","volume":"12","author":"Deng","year":"2019","journal-title":"OncoTargets Ther"},{"issue":"9","key":"10.1016\/j.ejca.2022.09.008_bib22","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.2021015114","article-title":"Impact of etoposide and ASCT on survival among patients < 65 years with stage II-IV PTCL; a population-based cohort study","volume":"140","author":"Brink","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.09.008_bib23","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single north american institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2022.09.008_bib24","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.09.008_bib25","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.09.008_bib26","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood.V106.11.2686.2686","article-title":"Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma (AITL). preliminary results in 9 patients treated in a single institution","volume":"106","author":"Joly","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.09.008_bib27","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1200\/jco.2010.28.15_suppl.8049","article-title":"Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma: results of the phase II RAIL trial\u2014a prospective study of the groupe d'etude des lymphomes de l'adulte (GELA)","volume":"28","author":"Joly","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2022.09.008_bib28","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/bloodadvances.2021006917","article-title":"Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients","volume":"6","author":"Haggenburg","year":"2022","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.ejca.2022.09.008_bib29","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.09.008_bib30","doi-asserted-by":"crossref","first-page":"92312","DOI":"10.18632\/oncotarget.21251","article-title":"Pretreatment epstein-barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2022.09.008_bib31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"Supplement 1","key":"10.1016\/j.ejca.2022.09.008_bib32","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood-2019-126194","article-title":"A phase II study of nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"134","author":"Bennani","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2022.09.008_bib33","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the ro-CHOP phase III study (conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.09.008_bib34","article-title":"Multi-center phase II study of oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma (PTCL)","author":"Ruan","year":"2020","journal-title":"ASH Annual Meeting"},{"issue":"8","key":"10.1016\/j.ejca.2022.09.008_bib35","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-d,g inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.ejca.2022.09.008_bib36","first-page":"1","article-title":"Advances in targeted therapy for malignant lymphoma","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"10.1016\/j.ejca.2022.09.008_bib37","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.ejca.2022.09.008_bib38","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.ejca.2022.09.008_bib39","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2019-123986","article-title":"A phase 2 study of the dual SYK\/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in relapsed\/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"134","author":"Horwitz","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ejca.2022.09.008_bib40","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1080\/17474086.2019.1652590","article-title":"Cyclosporine for angioimmunoblastic T-cell lymphoma: a literature review","volume":"12","author":"Omoto","year":"2019","journal-title":"Expert Rev Hematol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922007432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922007432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:38:05Z","timestamp":1760733485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922007432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":40,"alternative-id":["S0959804922007432"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.09.008","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}